Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02149173 · ClinicalTrials.gov registry record · NA
F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy
A NA study, sponsored by University of Washington.
- Terminated
- Registry status
- NA
- Development phase
- 29
- Enrollment target
NCT02149173 is a NA study that was terminated before completion, run by University of Washington. The registered enrollment target is 29 participants.
The verdict
NCT02149173, a NA study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- NA
- Development phase
- 29 participants
- Enrollment target
Study Summary
This clinical trial studies use of F-18 16 alpha-fluoroestradiol (\[F-18\] FES) positron emission tomography (PET)/computed tomography (CT) in measuring tumor hormone receptor expression in patients undergoing endocrine-targeted therapy for newly diagnosed breast cancer or breast cancer that has come back or spread to other places in the body. Comparing results of diagnostic procedures done before, during, and after hormone therapy may help measure a patient's response to treatment.
Interventions
- PROCEDURE Computed Tomography
- OTHER Laboratory Biomarker Analysis
- DRUG F-18 16 Alpha-Fluoroestradiol
- DRUG Fludeoxyglucose F-18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2010-09-15 |
| Est. Completion | 2021-01-13 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02149173
The ClinicalTrials.gov registry entry for NCT02149173 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Computed Tomography is the first listed.
NCT02149173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02149173 about?
NCT02149173 is a clinical study titled "F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy". This clinical trial studies use of F-18 16 alpha-fluoroestradiol (\[F-18\] FES) positron emission tomography (PET)/computed tomography (CT) in measuring tumor hormone receptor expression in patients undergoing endocrine-targeted therapy for newly diagnosed breast cancer or breast cancer that has com...
What is the current status of trial NCT02149173?
This trial is currently terminated. It is a NA study. The enrollment target is 29 participants. The study started on 2010-09-15. Estimated completion is 2021-01-13.
What interventions are being tested in trial NCT02149173?
The interventions under investigation include: Computed Tomography (PROCEDURE), Laboratory Biomarker Analysis (OTHER), F-18 16 Alpha-Fluoroestradiol (DRUG), Fludeoxyglucose F-18 (DRUG).
Who is sponsoring clinical trial NCT02149173?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.